Eike Wegener

Eike Wegener

Auto-generated profile, based on publicly available information

Eike Wegener

Department of Pediatrics and Pediatric Neurology, Georg August University, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2015 in Nature
Verified
Journal Article
Closed access
PDF file
JWJieqi Wang
Jieqi Wang
JWJan Eike Wegener
Jan Eike Wegener
THTeng-Wei Huang
Teng-Wei Huang
SSSmitha Sripathy
Smitha Sripathy
HJHector De Jesus-Cortes
Hector De Jesus-Cortes
APAndrew A Pieper
Andrew A Pieper

1 December 2010 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
CBCornelia Brendel
Cornelia Brendel
VBValery Belakhov
Valery Belakhov
HWHauke Werner
Hauke Werner
EWEike Wegener
Eike Wegener
JGJutta Gärtner
Jutta Gärtner
PHPeter Huppke
Peter Huppke
Thirty-five percent of patients with Rett syndrome carry nonsense mutations in the MECP2 gene. We have recently shown in transfected HeLa cells that readthrough of nonsense mutations in the MECP2 gene can be achieved by treatment with gentamicin and geneticin. This study was performed to test if readthrough can also be achieved in cells endogenously expressing mutant MeCP2 and to evaluate potentially more effective readthrough compounds. A mouse model was generated carrying the R168X mutation in the MECP2 gene. Transfected HeLa cells expressing mutated MeCP2 fusion proteins and mouse ear fibroblasts isolated from the new mouse model were treated with gentamicin and the novel aminoglycosides NB30, NB54, and NB84. The localization of the readthrough product was tested by immunofluorescence. Readthrough of the R168X mutation in mouse ear fibroblasts using gentamicin was detected but at lower level than in HeLa cells. As expected, the readthrough product, full-length Mecp2 protein, was located in the nucleus. NB54 and NB84 induced readthrough more effectively than gentamicin, while NB30 was less effective. Readthrough of nonsense mutations can be achieved not only in transfected HeLa cells but also in fibroblasts of the newly generated Mecp2 R168X mouse model. NB54 and NB84 were more effective than gentamicin and are therefore promising candidates for readthrough therapy in Rett syndrome patients.

13 August 2014 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PHPeter Huppke
Peter Huppke
EWEike Wegener
Eike Wegener
HBHelena Böhrer-Rabel
Helena Böhrer-Rabel
HBHanno J Bolz
Hanno J Bolz
BZBarbara Zoll
Barbara Zoll
CBCarsten Bergmann
Carsten Bergmann

26 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EWEike Wegener
Eike Wegener
CBCornelia Brendel
Cornelia Brendel
AFAndre Fischer
Andre Fischer
SHSwen Hülsmann
Swen Hülsmann
JGJutta Gärtner
Jutta Gärtner
PHPeter Huppke
Peter Huppke
Rett syndrome, one of the most common causes of mental retardation in females, is caused by mutations in the X chromosomal gene MECP2. Mice deficient for MeCP2 recapitulate some of the symptoms seen in patients with Rett syndrome. It has been shown that reactivation of silent MECP2 alleles can reverse some of the symptoms in these mice. We have generated a knockin mouse model for translational research that carries the most common nonsense mutation in Rett syndrome, R168X. In this article we describe the phenotype of this mouse model. In male MeCP2R168X mice life span was reduced to 12–14 weeks and bodyweight was significantly lower than in wild type littermates. First symptoms including tremor, hind limb clasping and inactivity occurred at age 27 days. At age 6 weeks nest building, rotarod, open-field and elevated plus maze experiments showed impaired motor performance, reduced activity and decreased anxiety-like behavior. Plethysmography at the same time showed apneas and irregular breathing with reduced frequency. Female MeCP2R168X mice showed no significant abnormalities except decreased performance on the rotarod at age 9 months. In conclusion we show that the male MeCP2R168X mice have a phenotype similar to that seen in MECP2 knockout mouse models and are therefore well suited for translational research. The female mice, however, have a much milder and less constant phenotype making such research with this mouse model more challenging.

21 May 2016 in BMC Neurology
Verified
Journal Article
Open access
PDF file
MKMatthias Kettwig
Matthias Kettwig
OEOrly Elpeleg
Orly Elpeleg
EWEike Wegener
Eike Wegener
SDSteffi Dreha-Kulaczewski
Steffi Dreha-Kulaczewski
MHMarco Henneke
Marco Henneke
PHPeter Huppke
Peter Huppke
Mutations in proteins involved in the glycosylphosphatidylinositol anchor biosynthesis and remodeling pathway are associated with autosomal recessive forms of intellectual disability. Recently mutations in the PGAP1 gene that codes for PGAP1, a protein localized in the endoplasmic reticulum responsible for the first step of the remodeling of glycosylphosphatidylinositol was linked to a disorder characterized by psychomotor retardation and facial dysmorphism. Whole exome sequencing (WES) was performed in siblings with severely delayed myelination and psychomotor retardation. Mutations in PGAP1 were confirmed by Sanger sequencing and RNA analysis. A literature search was performed to describe the emerging phenotype of PGAP1 related disease. WES resulted in the detection of two novel compound heterozygous mutations in PGAP1, one base pair insertion leading to a frame shift c.334_335InsA (p.A112fs) and a splice site mutation leading to exon skipping c.G1173C (p.L391L). A symptom not described in PGAP1 related disorder before but prominent in the siblings were recurrent apnea especially during sleep that persisted at least until age 2 years. Sequential cerebral MRI at age one and two year(s) respectively revealed frontal accentuated brain atrophy and significantly delayed myelination. We report siblings with two novel mutations in PGAP1. Other that the common symptoms related to PGAP1 mutations including non-progressive psychomotor retardation, neonatal feeding problems, microcephaly and brain atrophy these patients displayed severely delayed myelination and recurrent apneas thereby widing the clinical spectrum associated with such mutations.

4 July 2011 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MKMateusz Kolanczyk
Mateusz Kolanczyk
VMVictor Mautner
Victor Mautner
NKNadine Kossler
Nadine Kossler
RNRosa Nguyen
Rosa Nguyen
JKJirko Kühnisch
Jirko Kühnisch
LKLan Kluwe
Lan Kluwe
Neurofibromatosis type 1 (NF1) is a frequent genetic disease characterized by multiple benign tumours with increased risk for malignancy. There is currently no biomarker for tumour load in NF1 patients. In situ hybridization and quantitative real-time polymerase reaction were applied to investigate expression of cartilage-specific genes in mice bearing conditional inactivation of NF1 in the developing limbs. These mice do not develop tumours but recapitulate aspects of NF1 bone dysplasia, including deregulation of cartilage differentiation. It has been recently shown that NF1 tumours require for their growth the master regulator of cartilage differentiation SOX9. We thus hypothesized that some of the cartilage-specific genes deregulated in an Nf1Prx1 mouse model might prove to be relevant biomarkers of NF1 tumours. We tested this hypothesis by analyzing expression of the SOX9 target gene product melanoma-inhibitory activity/cd-rap (MIA) in tumour and serum samples of NF1 patients. Increased expression of Mia was found in Nf1-deficient cartilage in mice. In humans, MIA was expressed in all NF1-related tumours and its serum levels were significantly higher in NF1 patients than in healthy controls. Among NF1 patients, MIA serum levels were significantly higher in those with plexiform neurofibromas and in those with large number of cutaneous (> 1,000) or subcutaneous (> 100) neurofibromas than in patients without such tumours. Most notably, MIA serum levels correlated significantly with internal tumour burden. MIA is a potential serum biomarker of tumour load in NF1 patients which could be useful in following the disease course and monitoring the efficacy of therapies.